H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...
Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Moderna and Novavax shares ...
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
The Louisiana Department of Health noted yesterday that a 65-year-old hospital patient had died due to bird flu.
CNBC on MSN10d
Moderna stock plunges nearly 17% after company lowers 2025 sales forecast by $1 billionShares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of ...
Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its first death from the virus.
According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...
Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...
David Risinger, an analyst from Leerink Partners, reiterated the Buy rating on Vaxcyte (PCVX – Research Report). The associated price target ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback